Page last updated: 2024-10-15

deoxycytidylyl-(3'-5')-deoxyguanosine

Description

deoxycytidylyl-(3'-5')-deoxyguanosine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dCpdG : A (3'->5')-dinucleotide consisting of 2'-deoxyguanosine having a 2'-deoxycytidylyl-3-phospho moiety attached at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135509864
CHEBI ID62487
SCHEMBL ID8614074
MeSH IDM0114085

Synonyms (12)

Synonym
dcpdg
2'-deoxycytidylyl-(3'-5')-2'-deoxyguanosine
15178-66-2
deoxycytosine phosphate deoxyguanosine
2'-deoxycytidylyl-(3'->5')-2'-deoxyguanosine
CHEBI:62487 ,
deoxycytidylyl-(3'-5')-deoxyguanosine
EPITOPE ID:149180
SCHEMBL8614074
Q27131955
(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl (((2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9(6h)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl) hydrogen phosphate
STARBLD0001784
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
(3'->5')-dinucleotideAny dinucleotide where the two components are connected via a (3'->5')-phosphodiester linkage.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (48.28)18.7374
1990's7 (24.14)18.2507
2000's4 (13.79)29.6817
2010's4 (13.79)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]